REDDIE Consortium Holds Annual General Assembly Meeting 2025
On November 6, members of the REDDIE consortium gathered for the regular General Assembly meeting to review project progress and discuss upcoming mile...
We use cookies on our website. Cookies help make the website more user-friendly, efficient, and secure.
Please select your cookie preferences
Strictly necessary cookies are cookies required for the website to function and provide the basic information requested by the website user. These cookies are not used for tracking users.
YouTube cookies allow the playback of YouTube videos directly on our website. When YouTube cookies are used personal data or connection information, such as the IP address, may be transmitted to YouTube. By accepting YouTube cookies, you consent to the transfer of this data to YouTube. Please see our privacy policy for more information.
Randomised controlled trials (RCT) are the cornerstone of evidence-based medicine. However, the digitisation of real-world data (RWD) including data from devices, wearables, and electronic health records in large national registries provides opportunities to demonstrate efficacy and safety of innovative technologies including drugs, devices, diagnostics, and digital health. These data are particularly relevant to long-term conditions such as diabetes mellitus, where drugs, lifestyle interventions, and digital technologies often work together.
“In REDDIE, we will first define a typical target parameter of an RCT and then look for all people exposed to the same intervention in four comprehensive European real-world databases (Sweden, Denmark, Germany and England).
In this way, we ‘recreate’ the RCT trial within the real-world databases. Due to the large amount of real-world data we have available, we will get much faster answers to our research questions, tested in a much bigger cohort than this would ever be possible with RCTs.”
Dr Julia Mader, Medical University of Graz, REDDIE coordinator
